Recombinant Human Novel Coronavirus Nucleoprotein (N) (R203K, G204R) (Active) | CSB-EP3325GMY (M12)

(No reviews yet) Write a Review
SKU:
CSB-EP3325GMY (M12)
Availability:
3 - 7 Working Days
£178.40 - £574.40

Description

Recombinant Human Novel Coronavirus Nucleoprotein (N) (R203K, G204R) (Active) | CSB-EP3325GMY (M12) | Cusabio

Target Name: N

Uniprot No: P0DTC9

Species: Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV)

Source: E.coli

Tag Info: N-terminal 6xHis-tagged

Expression Region: 1-419aa (R203K,G204R)

Sequence Description: Full Length

Target Protein Sequence: MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAGLPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSKRTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKHWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA

Mol. Weight: 49.8 kDa

Purity: Greater than 96% as determined by SDS-PAGE.

Endotoxin: Not test.

Biological Activity: ①Measured by its binding ability in a functional ELISA. Immobilized N (CSB-EP3325GMY (M12)) at 2 μg/ml can bind N Mouse Monoclonal Antibody (CSB-MA33255A2m), the EC50 of N Mouse Monoclonal Antibody is 6.775-13.04 ng/ml. ②Measured by its binding ability in a functional ELISA. Immobilized N (CSB-EP3325GMY (M12)) at 2 μg/ml can bind N Recombinant Antibody (CSB-RA33255A1GMY), the EC50 of N Recombinant Antibody is 4.664-8.256 ng/ml.

Form: Lyophilized powder

Buffer: Lyophilized from 20 mM Tris-HCl, 0.5 M NaCl, 6% Trehalose, pH 8.0

Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.

View AllClose

0 Reviews

View AllClose